Evidence map›Paper›PMID 25566497›Full record

ArticleFrontiers in oncology2014

Pharmacological doses of daily ascorbate protect tumors from radiation damage after a single dose of radiation in an intracranial mouse glioma model.

Carole Grasso, Marie-Sophie Fabre, Sarah V Collis, M Leticia Castro, Cameron S Field, Nanette Schleich, Melanie J McConnell, Patries M Herst

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. High-dose intravenous vitamin C, a promising multi-targeting agent in the treatment of cancer.Journal of experimental & clinical cancer research : CR · 2021
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Carole GrassoMalaghan Institute of Medical Research , Wellington , New Zealand.
Marie-Sophie FabreSchool of Biological Sciences, Victoria University , Wellington , New Zealand.
Sarah V CollisSchool of Biological Sciences, Victoria University , Wellington , New Zealand.
M Leticia CastroSchool of Biological Sciences, Victoria University , Wellington , New Zealand.
Cameron S FieldMalaghan Institute of Medical Research , Wellington , New Zealand ; School of Biological Sciences, Victoria University , Wellington , New Zealand.
Nanette SchleichDepartment of Radiation Therapy, University of Otago , Wellington , New Zealand.
Melanie J McConnellMalaghan Institute of Medical Research , Wellington , New Zealand ; School of Biological Sciences, Victoria University , Wellington , New Zealand.
Patries M HerstMalaghan Institute of Medical Research , Wellington , New Zealand ; Department of Radiation Therapy, University of Otago , Wellington , New Zealand.
Victoria University of Wellington · NZUniversity of Otago · NZMalaghan Institute of Medical Research · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pharmacological ascorbate is currently used as an anti-cancer treatment, potentially in combination with radiation therapy, by integrative medicine practitioners. In the acidic, metal-rich tumor environment, ascorbate acts as a pro-oxidant, with a mode of action similar to that of ionizing radiation; both treatments kill cells predominantly by free radical-mediated DNA damage. The brain tumor, glioblastoma multiforme (GBM), is very resistant to radiation; radiosensitizing GBM cells will improve survival of GBM patients. Here, we demonstrate that a single fraction (6 Gy) of radiation combined with a 1 h exposure to ascorbate (5 mM) sensitized murine glioma GL261 cells to radiation in survival and colony-forming assays in vitro. In addition, we report the effect of a single fraction (4.5 Gy) of whole brain radiation combined with daily intraperitoneal injections of ascorbate (1 mg/kg) in an intracranial GL261 glioma mouse model. Tumor-bearing C57BL/6 mice were divided into four groups: one group received a single dose of 4.5 Gy to the brain 8 days after tumor implantation, a second group received daily intraperitoneal injections of ascorbate (day 8-45) after implantation, a third group received both treatments and a fourth control group received no treatment. While radiation delayed tumor progression, intraperitoneal ascorbate alone had no effect on tumor progression. Tumor progression was faster in tumor-bearing mice treated with radiation and daily ascorbate than in those treated with radiation alone. Histological analysis showed less necrosis in tumors treated with both radiation and ascorbate, consistent with a radio-protective effect of ascorbate in vivo. Discrepancies between our in vitro and in vivo results may be explained by differences in the tumor microenvironment, which determines whether ascorbate remains outside the cell, acting as a pro-oxidant, or whether it enters the cells and acts as an anti-oxidant.

Indexed as

GL261intracranial mouse glioma modelpharmacological ascorbateradiationradioprotectionradiosensitization

Identifiers

PMID25566497
PMCPMC4266032
OpenAlexW2085134251

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.